Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDA-002 in Diabetic Foot Ulcer With and Without Peripheral Arterial Disease
NCT02264288Phase 2Terminated
- Sponsor
- Celularity Inc.
- Start
- Oct 2014
- Primary completion
- Feb 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cenplacel in diabetic foot ulcer (DFU) (4 arms), sponsored by Celularity Inc. Primary endpoint: Percentage of Subjects With Complete Wound Closure of the Index Ulcer at 3 months. Started Oct 2014; status: terminated.
02
Drugs
cenplacel
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT02264288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02264288.